Second Genome CEO predicts paradigm shift with microbiome discovery

January 26, 2017 Christoph Graener

Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an interview at Biotech Showcase. Second Genome has a proprietary microbiome discovery platform that it is using to develop small molecules, peptide biologics and bacterial strains, with one clinical-stage candidate in the pipeline. The company is working with major pharma partners such as Pfizer Venture Fund and Roche Venture Fund, which were among the investors in a Series B round in Spring 2016 and the company is also looking for new partners to develop microbiome candidates in a broad range of diseases, including gastrointestinal conditions, cancer and the metabolic space.

Interviewer: Emily Hayes – Senior Writer, Scrip and The Pink Sheet
Interviewee: Glenn Nedwin – CEO, Second Genome

Previous Article
Double-barreled approach doubles survival times in recurrent glioma patients

Marty Duvall, newly-appointed CEO of San Diego-based gene therapy technology company Tocagen, explains how ...

Next Article
CBMG aims for large-scale CAR-T capacity

CBMG exec Tony Liu looks to differentiate CAR-T offerings partly based on ability to produce at a large sca...